or Ͼ 2 decades, nasal continuous positive airway pressure (CPAP) has been the cornerstone in the treatment of patients with moderate-to-severe obstructive sleep apnea (OSA). 1 Over the years, the therapeutic end points of CPAP application have evolved from abolishing respiratory events, including apneas, hypopneas, and snoring, to controlling respi-
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In more recent years, new devices have been developed that are designed to deliver autoadjustable positive airway pressure (APAP), meeting the patient's immediate pressure needs. 4 These devices have the theoretical advantage of stabilizing the upper airway during changing physiologic conditions, thereby circumventing the methodologic issues of manual pressure titration.
Although commercially available APAP devices have been shown to be useful in the assessment of CPAP requirements both in the sleep laboratory and at home, 5 it is still unknown whether the implicated APAP technologies are equally effective. 6 It has been shown that devices that run on different pressuredriving algorithms respond differently to changing pressure demands. 7 Therefore, we hypothesized that differences in the ability of various devices to stabilize sleep-disordered breathing should likewise occur. We compared two devices whose operation is based on different modes of sensing incipient upper airway obstruction. The operational characteristics of the AutoSet device (ResMed; Sydney, Australia) feature APAP guided by detection of flow limitation (APAPfl) of inspired air and the subsequent pressure adaptation. 8 The SOMNOsmart device (Weinmann, Hamburg, Germany) features APAP guided by the forced oscillation technique (APAPfot). 9 Pressure adjustments are based on changes in the measured impedance, and aim at keeping the resistance below a given percentage of wakefulness values. Favorable outcomes have been reported on the use of both aforementioned APAP devices regarding pressure titration in the sleep laboratory, 9 -14 as well as unattended use in the home environment. 15, 16 The present study was designed to compare the efficacy of these two APAP technologies in terms of effects on sleep quality, respiratory disturbance, and snoring indexes. Since adequate control of sleep-disordered breathing should be achieved at the lowest possible pressure level, it was also evaluated if the pressure output was appropriate in terms of magnitude and variability.
Materials and Methods

Subjects
Patients who demonstrated an apnea-hypopnea index (AHI) Ͼ 20/h plus an arousal index (AI) Ͼ 30/h (ie, Belgian criteria for reimbursement of nasal CPAP) were enrolled. Exclusion criteria included a history of prior uvulopalatopharyngoplasty, signs of severe nasal obstruction, excessive sleep disruption due to nonrespiratory causes, and COPD (ie, FEV 1 /FVC Ͻ 65%). None of the patients had symptoms and signs of congestive heart failure. No one refused to enter the study. Five patients had to be excluded after the registration because of intolerance or technical problems. Twenty-seven male and 3 females subjects (mean age, 53.8 Ϯ 10.1 years; body mass index, 30.5 Ϯ 4.5; FEV 1 /FVC, 0.76 Ϯ 0.06; AHI, 52.9 Ϯ 27.2/h; AI, 50.4 Ϯ 19.8/h) successfully completed the study (Ϯ SD). The study ran from January 2001 until July 2001. The participants gave written informed consent, and the trial was approved by the Ethical Review Board of our institution.
Sleep Studies
Polysomnography was carried out using a 19-channel digital polygraph (Morpheus; Medatec; Brussels, Belgium). A standardized sleep recording procedure was carried out, as previously described. 17 To record airflow, thermocouples plus nasal pressure cannulae were used during baseline studies. During the APAP trial, airflow was evaluated by measuring the respiratory pressure fluctuations in the nasal mask, which was connected via 4-mm-diameter flexible tubing to the built-in manometer (model 164PC01D37; Honeywell; Freeport, IL). Respiratory movements were recorded using thoracic and abdominal piezo-sensors (Sleepmate Technologies; Midlothian, VA). Sleep and respiratory events were manually scored in epochs of 30 s. Sleep stages were identified according to standard criteria. 18 The scoring of arousals was based on published guidelines. 19 The AI, the AHI, and the snoring index (ie, count of inspiratory snores per hour of sleep) were assessed according to previously described methods. 17 The CPAP level was also assessed manually in epochs of 30 s. A pressure value and corresponding sleep stage were allocated to each epoch.
Trial Protocol
Before carrying out a CPAP titration procedure, the patients were habituated on fixed CPAP home treatment. The CPAP was empirically set at a predicted pressure value of 7.9 Ϯ 1.8 cm H 2 O. 20 The CPAP compliance before the titration study was 4.7 Ϯ 2.5 h/night. The CPAP habituation period was 90.5 Ϯ 69.2 days. The patients were subsequently hospitalized to carry out an overnight study in which the AutoSet and SOMNOsmart devices were used in randomized order. The devices were covered in identical boxes for blinding purposes. After 4 h, the mask was disconnected from the first device and attached to the next device, which was then used for another 4 h. Both devices were programmed to a pressure range between 4 cm H 2 O and 14 cm H 2 O. The APAP devices were compared regarding their effect on relevant sleep and respiratory variables. The median positive airway pressure (P 50 ) and 95th percentile of positive airway pressure (P 95 ) values were computed differentially for the states of sleep and wakefulness. Finally, the P 50 /P 95 ratio was calculated. The lower the index, the greater the difference between P 50 and P 95 , which is indicative of increased pressure variability. 4 Scoring was done by one skilled technician, and reviewed by the first author of this article. Both were blinded to the treatment conditions.
Statistical Analysis
The paired t test was applied for evaluating differences between treatment conditions. To analyze whether the APAP devices behave differently in the sleep vs wake state, analysis of variance for repeated measurements was applied. This statistical procedure can be used to evaluate the interaction between different predictor variables (ie, the treatment condition and the sleep vs wake state) on therapeutic outcome (ie, pressure level). SPSS version 11.0 statistical software was used (SPSS; Chicago, IL). All presented data are mean Ϯ SD unless otherwise specified.
Results
Comparison of the two APAP devices showed no significant differences in the various sleep parameters, including time in bed, total sleep time, sleep efficiency, sleep stages, and AI (Table 1) . While the AHI was lower with the use of APAPfl (3.
In contrast, the snoring index was significantly lower with the application of APAPfl in comparison with APAPfot (35.3 Ϯ 53.7/h vs 111.6 Ϯ 175.4/h, respectively; p ϭ 0.01). Analysis of variance for repeated measurements showed a highly significant interaction between the treatment condition (APAPfl vs APAPfot) and the sleep vs waking condition with respect to pressure output (p ϭ 0.004). While P 50 and P 95 were significantly higher during sleep with APAPfl as compared with APAPfot, both variables rose from wakefulness to sleep in APAPfl, but decreased in APAPfot (Fig 1) . During sleep, the P 50 /P 95 was significantly lower with APAPfot as compared with APAPfl (0.65 Ϯ 0.15 vs 0.79 Ϯ 0.11, respectively; p Ͻ 0.001), indicating increased pressure variability in the former method. A typical example of pressure variability in a patient is shown in Figure 2 .
Discussion
The present study is one of the first clinical reports to compare the efficacy of two devices that are driven by different mechanisms for detection of upper airway obstruction. In this double-blind, randomized, cross-over trial, APAPfl (AutoSet device) and APAPfot (SOMNOsmart device) methods were compared. APAPfl provided a significantly better control of snoring, and resulted in a lower AHI (though not significantly) than APAPfot. These differences in respiratory parameters were best explained by differences in pressure profiles of the two devices. The median and 95th percentile of pressure levels rose significantly from wakefulness to sleep when using APAPfl, but fell paradoxically in the APAPfot treatment arm. In addition, APAPfot was subject to significantly higher pressure variability, which was indicated by a lower P 50 /P 95 ratio. Both the measurement of respiratory impedance based on forced oscillations applied to the upper airway, and the detection of inspiratory flow limitation have been used for monitoring of residual airway obstruction during CPAP titration. Lorino et al 21 demonstrated that the former method is more sensitive than the latter. Accordingly, the responses to the detection of disturbed breathing may be different in APAPfot and APAPfl methods. Another important difference between the two methods are the reaction times (change in pressure/change in time) that determine the rate at which the pressure adjustment will be completed. The slope of adaptation is steeper in both lowering and increasing the pressure in response to certain respiratory events with the APAPfot method. While a more sensitive and faster response to respiratory changes may predispose the APAPfot method to greater variability in pressure output, the handling of unphysiologic signals by the APAPfot method is also dissimilar from the APAPfl method. The AutoSet device, in contrast to the SOMNOsmart device, has a built-in system for the continuous monitoring of bias flow. The system is able to compensate for pressure drops due to excessive air leakage up to a flow rate of 0.4 L/s. 11 Since mask and/or mouth leaks often occur during sleep, this may in part explain why higher median positive pressure levels were found in the AutoSet device.
The pressure data from the present trial correspond to previously published results. The mean pressure values in a report 9 on the SOMNOsmart device are similar to our current findings. In that study, Randerath et al 9 reported that the SOMNOsmart device produced significantly lower pressure values in comparison with a manual titration procedure. As in our study, snoring was not eliminated in the APAPfl arm of the trial. Moreover, the P 50 and P 95 values of the AutoSet device are quite similar to previously published data on patients with a comparable severity of OSA and body mass index. 15 Since it is known that the pressure required to abolish snoring exceeds the pressure required to eliminate apneas by 2 cm H 2 O in Ͼ 90% of the patients, 22 it is evident that the better control of snoring obtained with APAPfl in this study is explained by the median CPAP level, which was on average 2.5 cm H 2 O higher than the median pressure produced by the APAPfot method.
From the present study, several issues emerge regarding our understanding of the operational features of APAP technology. The observation that the AHI, the principle outcome measure of this study, was not significantly different in two devices with markedly different pressure profiles requires further consideration. We hypothesize that there is a margin of pressure tolerance around an optimal CPAP level in a given patient at a given time. While obstructive breathing events will reappear when the pressure is reduced below a critical lower limit, raising the pressure above an upper threshold will induce air leakage and bring on unwarranted side effects. While essentially no data on the hypothetical upper pressure limit exist, it is known from the literature that "sham" nasal CPAP levels as low as 2 cm H 2 O may induce significant improvements in markers of sleepdisordered breathing. 23 Hence, the corresponding margin of pressure tolerance may comprise several centimeters of water. Within this conceptual margin, however, pressure adjustments will not appreciably affect sleep or breathing outcomes. We believe that the two APAP devices under study operated to a large extent in the presumed zone of pressure tolerance, which provides an explanation for the absence of a significant difference in effect on the AHI. Also in this concept, the absence of residual disturbed breathing at a given CPAP level does not by itself mean that this is the result of appropriate pressure adaptation. Second, it is unclear whether one measure of upper airway narrowing is sufficient to reliably titrate CPAP. It has been suggested that obstructive breathing events identified by the forced oscillation technique should not be scored unless corroborated by the concurrent presence of impaired ventilation, which requires the use of a pneumotachograph. 4, 24 Improved results, ie, normalization of the AHI at lower and more stable CPAP levels, might be obtained from the combined use of both techniques. Third, knowledge regarding the appropriate rate of pressure adjustment is lacking. From the present study it is clear that a fast pressure response is not necessarily synonymous with improved stabilization of breathing. On the contrary, excessive pressure variability may lead to inadequate control of snoring and sleep-disordered breathing.
In conclusion, the results of the present study show that a significantly better suppression of snoring is achieved by APAPfl than with APAPfot. Furthermore, AHI was lower with APAPfl than with APAPfot, although this difference was not statistically significant. The pressure profile of AutoSet device was strikingly different from the SOMNOsmart device in that AutoSet device had a higher median pressure but less pressure variability than the SOMNOsmart device. The difference in pressure profile best explains the differences in snoring and AHI observed with these two devices.
